The Belgian development financial institution BIO has allocated $6 million to the Rebuild Ukraine Fund (REBUF), the first private equity fund established during the war to invest in the Ukrainian economy. The fund is managed by Dragon Capital. The agreement was signed on August 18, 2026, in Kyiv by REBUF director Andriy Nosok and BIO CEO Joris Totte. The ceremony was attended by Belgian Deputy Prime Minister Maxim Prevo, Deputy Minister of Economy of Ukraine Vitaliy Kondratov, and Belgian Ambassador Luc Jacobs. Vitaliy Kondratov noted that the investment from Belgian BIO is a signal to the world about Ukraine's investment prospects. The REBUF fund supports small and medium enterprises in the healthcare, pharmaceuticals, agribusiness, and technology sectors. The fund plans to raise a total of $250 million, with the first closing taking place in January 2026 involving the EBRD and other organizations. BIO also supports Ukraine through other projects, investing €3 million in Bank Lviv and €7 million in NOTUS Energy.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.





Key Takeaways: Bio Protocol’s crypto has soared 90% following a $6.9M funding boost for its AI-native platform, Bio…





Latest Crypto Market Snapshot as of August 22, 2025 BTC Soars to $115,250.00 ETH Hits $4,450.75 XRP Climbs…


Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.



Key Takeaways: Bio Protocol’s crypto has soared 90% following a $6.9M funding boost for its AI-native platform, Bio…